U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07557446) titled 'A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)' on April 23.
Brief Summary: This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Osteogenesis Imperfecta (OI)
Intervention:
DRUG: AGA2115
Participants will receive AGA2115 administered by subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Angitia Biopharmaceuticals Guangzhou Limited
Disclaimer: Curated by HT Syndicat...